Among clinical studies that used the first-generation EGFR-TKI gefitinib, one study of first-line therapies in patients with EGFR-positive lung cancer and good PS reported a PFS of 10.8 months [3], whereas another conducted in patients with poor PS reported a shorter PFS of 6.5 months [13]. This evidence concerns the gene EGFR and lung cancer.